Merus NV Quote - MRUS

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

40.20

Bid

40.12

Ask

40.27

Volume

116,069

39.645 Day's Range 40.8199

33.8301 52 Week Range 61.61

Market Cap

2.752B

Previous Close

40.40

Open

40.38

Last Trade

40.19

Last Trade Time

10:05:28

Financial Volume

US$ 4,693,477

VWAP

40.437

Average Volume (3m)

622,191

Shares Outstanding

68,463,681

Dividend Yield

PE Ratio

0.00

Earnings Per Share (EPS)

Revenue

43.95M

Net Profit

-154.94M

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

Sector

Gen Med & Surgical Hospitals

Industry

Gen Med & Surgical Hospitals

Website

www.merus.nl

Headquarters

Utrecht, Utrecht, Nld

Founded

Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was US$40.40. Over the last year, Merus NV shares have traded in a share price range of US$ 33.8301 to US$ 61.61.

Merus NV currently has 68,463,681 shares outstanding. The market capitalization of Merus NV is US$2.77 billion.

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+;...

Form 8-K - Current report

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

BIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1Merus and...

Form 8-K - Current report

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full...

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.45	1.1320754717	39.75	41.82	39.22	559450	40.49964794	CS
4	-1.76	-4.19447092469	41.96	47.75	37.77	700345	41.08906654	CS
12	-8.8	-17.9591836735	49	55.39	37.77	622191	43.68658858	CS
26	-14.65	-26.709206928	54.85	56.39	37.77	549933	47.41836991	CS
52	6.13	17.9923686528	34.07	61.61	33.8301	682895	49.01178607	CS
156	16.44	69.1919191919	23.76	61.61	12.03	444314	35.87128186	CS
260	23	133.720930233	17.2	61.61	10.18	344267	32.76576238	CS

MRUS - Frequently Asked Questions (FAQ)

What is the current Merus NV share price?

The current share price of Merus NV is US$ 40.20

How many Merus NV shares are in issue?

Merus NV has 68,463,681 shares in issue

What is the market cap of Merus NV?

The market capitalisation of Merus NV is USD 2.77B

What is the 1 year trading range for Merus NV share price?

Merus NV has traded in the range of US$ 33.8301 to US$ 61.61 during the past year

What is the reporting currency for Merus NV?

Merus NV reports financial results in USD

What is the latest annual turnover for Merus NV?

The latest annual turnover of Merus NV is USD 43.95M

What is the latest annual profit for Merus NV?

The latest annual profit of Merus NV is USD -154.94M

What is the registered address of Merus NV?

The registered address for Merus NV is UPPSALALAAN 17, UTRECHT, UTRECHT, 3584 CT

What is the Merus NV website address?

The website address for Merus NV is www.merus.nl

Which industry sector does Merus NV operate in?

Merus NV operates in the GEN MED & SURGICAL HOSPITALS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SLXNSilexion Therapeutics Corporation	US$ 1.1501 (98.29%)	160.86M
RNAZTransCode Therapeutics Inc	US$ 11.3499 (66.18%)	13.18M
YIBOPlanet Image International Ltd	US$ 4.92 (59.74%)	46.2M
TRIBTrinity Biotech PLC	US$ 1.09 (43.42%)	96.27M
NVVENuvve Holding Corporation	US$ 3.8899 (40.94%)	407.17k
LPTXLeap Therapeutics Inc	US$ 0.6587 (-70.72%)	7.09M
STSSSharps Technology Inc	US$ 0.4591 (-68.55%)	10.67M
SABSSAB Biotherapeutics Inc	US$ 2.1775 (-50.06%)	856.51k
MGOLMGO Global Inc	US$ 0.1762 (-37.74%)	12.95M
JBLUJetBlue Airways Corporation	US$ 6.1325 (-24.20%)	49.42M
HEPAHepion Pharmaceuticals Inc	US$ 0.2073 (25.64%)	219.75M
NVDANVIDIA Corporation	US$ 121.1478 (2.30%)	208.42M
SLXNSilexion Therapeutics Corporation	US$ 1.1501 (98.29%)	160.86M
TRIBTrinity Biotech PLC	US$ 1.09 (43.42%)	96.27M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.518151 (25.73%)	82.7M